Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 59.0%

Neg 0% Neu 59% Pos 0%

Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $12.